Omeros Co. (NASDAQ:OMER) shares dropped 6.1% during mid-day trading on Friday . The company traded as low as $15.14 and last traded at $15.19. Approximately 541,857 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 693,416 shares. The stock had previously closed at $16.17.

OMER has been the subject of a number of analyst reports. Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Wedbush restated an “outperform” rating and issued a $47.00 price objective on shares of Omeros in a research report on Tuesday, November 28th. Maxim Group set a $24.00 price objective on Omeros and gave the company a “buy” rating in a research report on Friday, October 20th. HC Wainwright set a $30.00 price objective on Omeros and gave the company a “buy” rating in a research report on Thursday, January 4th. Finally, Cowen cut Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $34.14.

The firm has a market capitalization of $729.18, a PE ratio of -11.78 and a beta of 3.30. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.18. The business had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. The firm’s quarterly revenue was up 91.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.34) earnings per share. sell-side analysts anticipate that Omeros Co. will post -0.98 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of OMER. C M Bidwell & Associates Ltd. purchased a new stake in shares of Omeros in the fourth quarter valued at approximately $106,000. First Interstate Bank purchased a new stake in shares of Omeros during the third quarter worth approximately $108,000. Legal & General Group Plc increased its position in shares of Omeros by 7.8% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares in the last quarter. Hanseatic Management Services Inc. increased its position in shares of Omeros by 10,919.6% during the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,592 shares in the last quarter. Finally, Malaga Cove Capital LLC purchased a new stake in shares of Omeros during the fourth quarter worth approximately $242,000. Institutional investors and hedge funds own 50.26% of the company’s stock.

WARNING: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/02/02/omeros-omer-trading-down-6-1.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.